IFNAR2 (E7Z4M) Rabbit mAb #53883
- WB
- IP
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 95 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:400 |
| Flow Cytometry (Live) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
IFNAR2 (E7Z4M) Rabbit mAb recognizes endogenous levels of total IFNAR2 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human IFNAR2 protein.
Background
Interferon alpha/beta receptor 2 (IFNAR2) is one of the two protein subunits that comprise the type I interferon (IFN-I) surface receptor. IFNAR2 is a class II helical cytokine receptor with an ectodomain composed of two fibronectin type III-like subdomains, D1 and D2, and an unstructured intracellular domain (ICD) (1,2). IFNAR2 is expressed on most nucleated cells (3). IFN-Is bind the IFN receptor, leading to the dimerization of IFNAR2 and IFNAR1 subunits, and the activation of Janus family kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathways (4,5). JAK1 is associated with IFNAR2, and STAT1 and STAT2 are constitutively bound to the ICD of IFNAR2 (6,7). The formation of the transcription factor IFN-stimulated gene factor 3 (ISGF3), which is a complex made up of the pSTAT1-pSTAT2 heterodimer and interferon regulatory factor 9 (IRF-9), leads to the transcription of interferon-stimulated genes (ISGs) (8). IFN-I subtypes have differential binding affinity toward IFNAR2, contributing to differences in response potency (9). In contrast, IFNαs all bind IFNAR1 with a low affinity and only IFNβ binds IFNAR1 with a relatively higher affinity (10). IFN-I signaling mediates various cellular responses, including antiviral responses, immunomodulatory responses, and antiproliferative effects (11). In the tumor microenvironment (TME), the presence of IFN-I signaling is associated with “hot” tumors in which key effector immune cells are present and is predictive of therapeutic response, whereas suppressed IFN-I signaling in the TME is associated with tumor progression and poorer outcomes (12,13). IFN-I signaling is being investigated as a therapeutic target for cancer, autoimmunity, sepsis, and viral infection (14,15).
- Bazan, J.F. (1990) Proc Natl Acad Sci U S A 87, 6934-8.
- Novick, D. et al. (1994) Cell 77, 391-400.
- Cohen, B. et al. (1995) Mol Cell Biol 15, 4208-14.
- Shuai, K. et al. (1992) Science 258, 1808-12.
- Saleh, A.Z. et al. (2002) Biochemistry 41, 11261-8.
- Arimoto, K.I. et al. (2017) Nat Struct Mol Biol 24, 279-289.
- Schreiber, G. (2017) J Biol Chem 292, 7285-7294.
- Lavoie, T.B. et al. (2011) Cytokine 56, 282-9.
- Lamken, P. et al. (2004) J Mol Biol 341, 303-18.
- Platanias, L.C. (2005) Nat Rev Immunol 5, 375-86.
- Katlinski, K.V. et al. (2017) Cancer Cell 31, 194-207.
- Katlinskaya, Y.V. et al. (2016) Cell Rep 15, 171-180.
- Trinchieri, G. (2010) J Exp Med 207, 2053-63.
- Schreiber, G. (2020) Front Immunol 11, 595739.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.